Skip to main content
رجوع
CMOPF logo

Cosmo Pharmaceuticals N.V.

جودة البيانات: 100%
ذروة بيع
CMOPF
OTC Healthcare Drug Manufacturers - General
KWD 101.45
▲ KWD 6.26 (6.58%)
القيمة السوقية: 1.64B
نطاق اليوم
KWD 97.00 KWD 101.45
نطاق 52 أسبوعًا
KWD 55.00 KWD 169.90
حجم التداول
200
متوسط 50 يوم / 200 يوم
KWD 140.81 / KWD 98.97
الإغلاق السابق
KWD 95.19

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E -452.4 0.4
P/B 3.4 2.9
ROE % -0.7 3.7
Net Margin % -3.5 3.8
Rev Growth 5Y % 12.7 10.0
D/E 0.0 0.2

النقاط الرئيسية

Revenue grew 12.66% annually over 5 years — strong growth
Earnings declined -102.72% over the past year
Debt/Equity of 0.01 — conservative balance sheet
Negative free cash flow of -15.84M
Revenue growth is decelerating — 1Y growth trails 5Y average by 73.37%
Capital efficient — spends only 4.04% of revenue on capex

النمو

Revenue Growth (5Y)
12.66%
Revenue (1Y)-60.71%
Earnings (1Y)-102.72%
FCF Growth (3Y)N/A

الجودة

Return on Equity
-0.74%
ROIC-1.62%
Net Margin-3.46%
Op. Margin-10.00%

الأمان

Debt / Equity
0.01
Current Ratio7.18
Interest Coverage-57.54

التقييم

P/E Ratio
-452.43
P/B Ratio3.41
EV/EBITDAN/A
Dividend Yield0.02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -60.71% Revenue Growth (3Y) 6.29%
Earnings Growth (1Y) -102.72% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 12.66% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 104.82M Net Income (TTM) -3.63M
ROE -0.74% ROA -0.59%
Gross Margin 46.53% Operating Margin -10.00%
Net Margin -3.46% Free Cash Flow (TTM) -15.84M
ROIC -1.62% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.01 Current Ratio 7.18
Interest Coverage -57.54 Dividend Yield 0.02%
Valuation
P/E Ratio -452.43 P/B Ratio 3.41
P/S Ratio 15.67 PEG Ratio 4.84
EV/EBITDA N/A Dividend Yield 0.02%
Market Cap 1.64B Enterprise Value 1.59B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 104.82M 266.79M 92.78M 102.09M 65.07M
Net Income -3.63M 133.24M -4.93M 17.23M 21.67M
EPS (Diluted) -0.23 8.12 -0.31 1.05 1.28
Gross Profit 48.77M 246.92M 53.44M 83.33M 49.93M
Operating Income -10.48M 148.88M 6.15M 28.06M 11.10M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 611.97M 646.77M 553.98M 759.59M 805.56M
Total Liabilities 123.32M 141.68M 124.94M 295.80M 292.88M
Shareholders' Equity 481.78M 498.33M 422.16M 456.93M 505.28M
Total Debt 4.26M 2.20M 1.84M 173.60M 169.92M
Cash & Equivalents 55.80M 44.30M 50.28M 185.83M 198.56M
Current Assets 183.08M 202.26M 102.23M 306.10M 275.85M
Current Liabilities 25.49M 48.27M 25.71M 194.95M 21.24M